Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
$3.12
-11.6%
$3.77
$3.25
$17.50
$2.41M1.091,859 shs125,682 shs
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
$1.60
-0.6%
$1.41
$1.15
$23.80
$2.65M0.511.31 million shs299,774 shs
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$0.00
$0.00
$0.00
$710K-0.21135,329 shsN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$3.71
-2.9%
$3.61
$2.85
$29.44
$2.81M0.01113,685 shs6,381 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
-11.61%-9.30%+4.00%-18.75%+132.84%
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
0.00%+5.96%+26.98%-7.35%-62.96%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00%0.00%0.00%-50.00%0.00%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
0.00%-1.07%-5.84%+21.24%-64.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
1.0744 of 5 stars
0.02.00.00.03.32.50.6
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
0.00
N/AN/AN/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
2.00
HoldN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00
N/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NPHC, QLGN, GLMD, and BCTXF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/4/2025
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/AN/AN/AN/A($4.55) per shareN/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/AN/AN/AN/A$33.02 per shareN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$4.98M0.55N/AN/A($20.31) per share-0.18
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
-$3.68M-$3.84N/AN/AN/AN/A-786.77%N/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
-$6.91M-$16.66N/AN/AN/A-28.75%-24.98%8/26/2025 (Estimated)
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
-$13.42MN/A0.00N/AN/AN/A-424.18%7/1/2025 (Estimated)

Latest NPHC, QLGN, GLMD, and BCTXF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/22/2025Q1 2025
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/A-$0.62N/A-$0.62N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/AN/AN/AN/AN/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/AN/AN/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
N/A
0.07
0.07
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/A
7.03
7.03
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/A
0.52
0.52

Institutional Ownership

CompanyInstitutional Ownership
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
0.10%
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
76.14%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
3.18%
CompanyEmployeesShares OutstandingFree FloatOptionable
BriaCell Therapeutics Corp. stock logo
BCTXF
BriaCell Therapeutics
8772,000N/ANot Optionable
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
201.65 million516,000Not Optionable
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
47.10 billion2.73 billionNot Optionable
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
50736,000723,000Not Optionable

Recent News About These Companies

Qualigen Therapeutics to participate in next funding round for NanoSynex
Qualigen to participate in next funding round for NanoSynex
Qualigen announces $4.5M private placement of Preferred Shares

New MarketBeat Followers Over Time

Media Sentiment Over Time

BriaCell Therapeutics stock logo

BriaCell Therapeutics OTCMKTS:BCTXF

$3.12 -0.41 (-11.61%)
As of 06/13/2025

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

Galmed Pharmaceuticals stock logo

Galmed Pharmaceuticals NASDAQ:GLMD

$1.60 -0.01 (-0.62%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$1.62 +0.02 (+1.25%)
As of 06/13/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Nutra Pharma stock logo

Nutra Pharma OTCMKTS:NPHC

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

Qualigen Therapeutics stock logo

Qualigen Therapeutics NASDAQ:QLGN

$3.71 -0.11 (-2.88%)
Closing price 06/13/2025 03:59 PM Eastern
Extended Trading
$3.71 0.00 (0.00%)
As of 06/13/2025 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.